Large-Scale Chemical–genetics Yields New M. Tuberculosis Inhibitor Classes
Da Silva, Israel
MetadataShow full item record
CitationJohnson, Eachan O, Emily LaVerriere, Emma Office, Mary Stanley, Elisabeth Meyer, Tomohiko Kawate, James E Gomez, Rebecca E Audette, Nirmalya Bandyopadhyay, Natalia Betancourt, Kayla Delano, Israel Da Silva, Joshua Davis, Christina Gallo, Michelle Gardner, Aaron J Golas, Kristine M. Guinn, Sofia Kennedy, Rebecca Korn, Jennifer A McConnell, Caitlin E. Moss, Kenan C Murphy, Raymond M. Nietupski, Kadamba G. Papavinasasundaram, Jessica T. Pinkham, Paula A. Pino, Megan K Proulx, Nadine Ruecker, Naomi Song, Matthew Thompson, Carolina Trujillo, Shoko Wakabayashi, Joshua B Wallach, Christopher Watson, Thomas R. Ioerger, Eric S. Lander, Brian K. Hubbard, Michael H. Serrano-Wu, Sabine Ehrt, Michael Fitzgerald, Eric J. Rubin, Christopher M. Sassetti, Dirk Schnappinger, and Deborah T. Hung. 2019. Large-scale Chemical-genetics Yields New M. Tuberculosis Inhibitor Classes. Nature 571, no. 7763: 72-78.
AbstractNew antibiotics are needed to combat rising resistance, with new Mycobacterium tuberculosis (Mtb) drugs of highest priority. Conventional whole-cell and biochemical antibiotic screens have failed. We developed a novel strategy termed PROSPECT (PRimary screening Of Strains to Prioritize Expanded Chemistry and Targets) in which we screen compounds against pools of strains depleted for essential bacterial targets. We engineered strains targeting 474 Mtb essential genes and screened pools of 100-150 strains against activity-enriched and unbiased compounds libraries, probing >8.5-million chemical-genetic interactions. Primary screens identified >10-fold more hits than screening wild-type Mtb alone, with chemical-genetic interactions providing immediate, direct target insight. We identified >40 novel compounds targeting DNA gyrase, cell wall, tryptophan, folate biosynthesis, and RNA polymerase, as well as inhibitors of a novel target EfpA. Chemical optimization yielded EfpA inhibitors with potent wild-type activity, thus demonstrating PROSPECT’s ability to yield inhibitors against novel targets which would have eluded conventional drug discovery.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:42066797
- HMS Scholarly Articles 
Contact administrator regarding this item (to report mistakes or request changes)